Biocept Aandeel

Biocept Goodwill

Delisted

Goodwill van Biocept (BIOC) per 22 aug 2026.

Goodwill

0,00USD

Laatst bijgewerkt:

Goodwill van Biocept is 2026 0,00 USD. Goodwill van Biocept was 2025 0,00 USD. Het is daarmee % lager lager dan het jaar ervoor.

De Biocept Goodwill historie

  • 3 jaar

  • 10 jaar

  • 25 jaar

  • Max

Goodwill
Date
Goodwill
1 jan 2014
0,00 USD
1 jan 2015
0,00 USD
1 jan 2016
0,00 USD
1 jan 2017
0,00 USD
De Biocept Goodwill historie
JAARGoodwillYoY
0,00USD
0,00USD
0,00USD
0,00USD
Access this data via the Eulerpool API

Biocept Aandelenanalyse

Wat doet Biocept? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is een van de meest populaire bedrijven op Eulerpool.

Veelgestelde vragen over het aandeel Biocept

Op Eulerpool vindt u de volledige historische ontwikkeling van Goodwill Biocept sinds 2006 – met jaarlijkse waarden, grafieken en gedetailleerde analyse.

Goodwill is de premie die wordt betaald boven de reële marktwaarde bij een overname.

USD van Goodwill is een belangrijke factor voor beleggers. Veranderingen in deze maatstaf kunnen sterke signalen geven voor toekomstige koersontwikkelingen.

Access this data via the Eulerpool API

Balans — Biocept

Alle kengetallen — Biocept